Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs) ; volume:5 ; number:03 ; year:2020 ; pages:216-222
Indian Journal of Cardiovascular Disease in Women WINCARS ; 5, Heft 03 (2020), 216-222
- Contributor
-
Jyotsna, M.
Hemalatha, Y.
- DOI
-
10.1055/s-0040-1716786
- URN
-
urn:nbn:de:101:1-2020122110505954783911
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jyotsna, M.
- Hemalatha, Y.
Other Objects (12)
Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States
Potential drug–drug interactions in patients with cardiovascular diseases: findings from a prospective observational study
Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
A Review of Daclatasvir Drug–Drug Interactions
Drug–Drug Interactions with Direct Oral Anticoagulants
Extracting drug-drug interactions from biomedical texts
Strategies for avoiding typical drug–drug interactions and drug-related problems in patients with vascular diseases
Drug therapy problems among hospitalized patients with cardiovascular disease
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Lurasidone drug-drug interaction studies: a comprehensive review
Case report: Medical cannabis—warfarin drug-drug interaction
DPDDI: a deep predictor for drug-drug interactions
Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States
Potential drug–drug interactions in patients with cardiovascular diseases: findings from a prospective observational study
Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
A Review of Daclatasvir Drug–Drug Interactions
Drug–Drug Interactions with Direct Oral Anticoagulants
Extracting drug-drug interactions from biomedical texts
Strategies for avoiding typical drug–drug interactions and drug-related problems in patients with vascular diseases
Drug therapy problems among hospitalized patients with cardiovascular disease
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Lurasidone drug-drug interaction studies: a comprehensive review
Case report: Medical cannabis—warfarin drug-drug interaction
DPDDI: a deep predictor for drug-drug interactions
Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States
Potential drug–drug interactions in patients with cardiovascular diseases: findings from a prospective observational study
Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
A Review of Daclatasvir Drug–Drug Interactions
Drug–Drug Interactions with Direct Oral Anticoagulants
Extracting drug-drug interactions from biomedical texts
Strategies for avoiding typical drug–drug interactions and drug-related problems in patients with vascular diseases
Drug therapy problems among hospitalized patients with cardiovascular disease
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Lurasidone drug-drug interaction studies: a comprehensive review
Case report: Medical cannabis—warfarin drug-drug interaction